In the most recent trading session, Merck (MRK) closed at $80.32, indicating a -1.27% shift from the previous trading day.
Merck (MRK) closed at $81.35 in the latest trading session, marking a +2.55% move from the prior day.
I use option collars on struggling stocks like Merck & Co., Inc. to cap downside risk while maintaining upside potential, especially when the technicals look uncertain. My MRK collar trade earlier this year limited losses compared to straight ownership, demonstrating why I favor this strategy for "dog" stocks. Currently, MRK stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet.
Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Company Participants Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M.
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies.
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.
Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, patritumab deruxtecan (HER3-DXd) based on the HERTHENA-Lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies has.